Jennison Associates’s Rubius Therapeutics RUBY Stock Holding History
Bought
Maintained
Sold
Other funds holding RUBY
AG
Jennison Associates's RUBY Position: Q4 2019 in Review
Jennison Associates sold out of Rubius Therapeutics (RUBY) in Q4 2019, closing a stake of 434,550 shares — an estimated $3.41M sold.
Jennison Associates first reported a position in RUBY in Q3 2018 and held it in 5 quarters. The position peaked at $11.3M in Q3 2018. 76 funds tracked by Wall St. Rank hold RUBY as of Q4 2019.
- Jennison Associates reported no remaining Rubius Therapeutics position as of Q4 2019 after selling out during the quarter.
- Jennison Associates sold 434,550 Rubius Therapeutics shares in Q4 2019, an estimated $3.41M.
- Jennison Associates first reported a position in Rubius Therapeutics in Q3 2018 and held it in 5 quarters.
- Jennison Associates's Rubius Therapeutics position peaked at $11.3M in Q3 2018.
- 76 funds tracked by Wall St. Rank held Rubius Therapeutics as of Q4 2019.
Based on Jennison Associates's 13F filing for Q4 2019, filed 7 Feb 2020.